Working… Menu

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02914990
Recruitment Status : Completed
First Posted : September 26, 2016
Last Update Posted : July 18, 2019
Information provided by (Responsible Party):
Betta Pharmaceuticals Co., Ltd.

Brief Summary:
The main objective of this study is to evaluate the safety and tolerability of BPI-15086.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Drug: BPI-15086 Phase 1

Detailed Description:
The main objective of this study is to evaluate the safety and tolerability of BPI-15086. In addition, the anti-cancer effect of BPI-15086 in EGFR T790M mutation-positive advanced NSCLC patients who have progressed on a previous EGFR tyrosine kinase inhibitor therapy will also be evaluated. Biomarkers related to the efficacy of BPI-15086 will be investigated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of BPI-15086 in Patients With Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed on Previous EGFR Tyrosine Kinase Inhibitor Therapy
Actual Study Start Date : December 29, 2016
Actual Primary Completion Date : March 7, 2019
Actual Study Completion Date : March 7, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: BPI-15086
BPI-15086, orally administered daily
Drug: BPI-15086
BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.

Primary Outcome Measures :
  1. Adverse events [ Time Frame: 18 months ]
    Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03

Secondary Outcome Measures :
  1. Cmax [ Time Frame: 4 weeks ]
  2. Half life [ Time Frame: 4 weeks ]
  3. AUC [ Time Frame: 4 weeks ]
  4. Objective Response Rate [ Time Frame: 12 weeks ]
  5. Progression-Free Survival [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed, locally advanced or metastatic NSCLC patients, who is not suitable for surgery or radiotherapy
  • Radiological documentation of disease progression while on a previous continuous EGFR TKI (e.g. icotinib, gefitinib, afatinib, neratinib, dacomitnib, or erlotinib) treatment
  • Patients must fulfil one of the following:

    • Confirmation that the tumour harbours EGFR sensitivity mutation (exon 19 deletion, L858R and L861R, G719X)
    • Must have experienced clinical benefit from EGFR TKIs, according to the Jackman criteria
  • Confirmation of T790M mutation positive after disease progression on EGFR TKIs
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and estimated life expectancy of at least 12 weeks
  • Measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST1.1)
  • Adequate bone marrow, hepatic, and renal function
  • Women: For pre-menopausal women who have a childbearing potential, they must have a pregnancy test within 7 days before starting treatment. The serum or urine pregnancy test must be negative and must be non-lacking; all patients (whether male or female) should be Adequate barrier contraceptive measures during the entire treatment period and 3 months after the end of treatment
  • Have signed Informed Consent Form

Exclusion Criteria:

  • Any other malignancy within 5 years of the first dose of study treatment
  • Radiotherapy for target lesion within 4 weeks of the first dose of study treatment.
  • From the treatment of reversible EGFR TKI drugs (e.g. Ectinib, Gefitinib, Erlotinib) to the first use of drugs, the time did not exceed 8 days or 5 half-lives (take the long time);Irreversible EGFR TKI drugs (e.g. Alfatinib, Neratinib, Dacomitinib) did not last more than 14 days or 5 half-lives (take the long term)
  • Investigational agents or anticancer drugs (Including cytotoxic chemotherapy) from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment
  • Prior treatment with other third generation EGFR TKIs, including osimertinib, rociletinib, EGF816, olmutinib, ASP8273 and avitinib
  • Brain/meninges metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to start of study treatment
  • History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease, radiological documentation of idiopathic pulmonary fibrosis at baseline; uncontrolled pleural effusion/pericardial effusion
  • Any evidence of severe or uncontrolled systemic diseases, including CTCAE 2 or higher active infection, uncontrolled hypertension, unstable angina pectoris, congestive cardiac failure and severe liver/renal or metabolic disease
  • Active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)
  • History of organ transplant; had surgery or severe injury within 4 weeks
  • Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval >240msec, or QRS> 110 msec
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval
  • Poorly controlled hyperglycemia(fasting blood glucose level ≥7.0 mmol/L).
  • Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the exception of alopecia
  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of BPI-15086
  • It is known that the study drug or any of its excipients (microcrystalline cellulose, lactose, crospovidone, hydroxypropyl cellulose, magnesium stearate) are severely allergic
  • CYP3A4 strong inhibitors or inducers or Chinese herbal medicine for anti-tumor indications were used within 1 week before the first dose
  • Abuse of drugs and medical, psychological or social conditions in patients may interfere with participating in the study or assessment of the results of the study
  • Any condition that is unstable or may compromise patient safety and compliance with the study
  • Researchers believe that patients who are not suitable for treatment with this regimen

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02914990

Layout table for location information
China, Beijing
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing, China, 100021
Sponsors and Collaborators
Betta Pharmaceuticals Co., Ltd.
Layout table for investigator information
Study Chair: Yuankai Shi, MD Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Layout table for additonal information
Responsible Party: Betta Pharmaceuticals Co., Ltd. Identifier: NCT02914990    
Other Study ID Numbers: BTP-26511
First Posted: September 26, 2016    Key Record Dates
Last Update Posted: July 18, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms